NASDAQ:RAPP | Free Cash Flow | Rapport Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2023-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$13.06M$86,000.00-$13.15M
2025-12-31-$24.7M$169,000.00-$24.87M
2025-03-31-$20.24M$291,000.00-$20.53M
2024-12-31-$14.45M$226,000.00-$14.67M
2024-03-31-$17.62M$1.07M-$18.69M
2023-12-31-$10.36M$1.44M-$11.79M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$87.47M$616,000.00-$88.09M
2024-12-31-$64.83M$2.41M-$67.23M
2023-12-31-$27.18M$1.64M-$28.82M